EDIVROEditorial illustrationnews
Teva signs US rights deal for two Samsung Bioepis biosimilars
Teva and Samsung Bioepis signed a licensing deal covering US commercial rights to two FDA-approved immunology biosimilars. The companies expect the transaction to close by the end of 2026, subject to approvals and other conditions.
Edivro Company News · Original attributed summary. Source announcement: 2026-11-03.
